Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cell culture studies of the efficacy and barrier to resistance of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir against hepatitis C virus genotypes 2a, 2b and 2c

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Genome Sequence of an Unknown Subtype of Hepatitis C Virus Genotype 6: Another Piece for the Taxonomic Puzzle

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Virus Adaptation and Selection Following Challenge of Animals Vaccinated against Classical Swine Fever Virus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Replicons of a rodent hepatitis C model virus permit selection of highly permissive cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Introduction of highly efficient therapies with direct-acting antivirals (DAA) for patients with chronic hepatitis C virus (HCV) infection offers exceptional opportunities to globally control this deadly disease. For achieving this ambitious goal, it is essential to prevent antiviral resistance against the most optimal first-line and retreatment DAA choices. We performed independent comparisons of the efficacy and barrier to resistance of pangenotypic DAA regimens for HCV genotype 2 infections, using previously, and newly developed efficient cell culture adapted strains of subtypes 2a, 2b and 2c. With applied experimental cell culture conditions, combination treatment with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir DAA-regimens was efficient in eradicating HCV infections, in contrast to single drug treatments frequently leading to viral escape. Sequence analysis of drug targets from recovered viruses revealed known resistance associated substitutions (RAS) emerging in the NS3 protease or NS5A after treatment failure, which were genetically stable after viral passage and exhibited significant phenotypic resistance. After sofosbuvir treatment failure, only a genotype 2a virus harbored NS5B-RAS S282T and thus had decreased susceptibility to nucleotide analogs (nucs). However, in most cases viral escape from sofosbuvir led to other NS5B substitutions with maintained drug susceptibility, and in one case no changes in NS5B were detected. For a genotype 2b virus, after treatment failure with sofosbuvir/velpatasvir, retreatment with glecaprevir/pibrentasvir maintained efficacy due to the high barrier to resistance and low cross-resistance of pibrentasvir. Our findings suggest slight superiority of glecaprevir/pibrentasvir for genotype 2b in culture, which could have potential therapeutic interest meriting more definitive investigations in the clinic.

OriginalsprogEngelsk
TidsskriftAntimicrobial Agents and Chemotherapy
Vol/bind64
Udgave nummer3
ISSN0066-4804
DOI
StatusUdgivet - 21 feb. 2020

Bibliografisk note

Copyright © 2019 American Society for Microbiology.

ID: 58597351